Literature DB >> 17508990

Does naltrexone affect craving in abstinent opioid-dependent patients?

Boukje A G Dijkstra1, Cor A J De Jong, Sarah M Bluschke, Paul F M Krabbe, Cees P F van der Staak.   

Abstract

Naltrexone blocks the opioid receptors that modulate the release of dopamine in the brain reward system and therefore blocks the rewarding effects of heroin and alcohol. It is generally assumed that naltrexone leads to reduction of craving, but few studies have been performed to prove this. The purpose of the present study was to examine the effect of the administration of naltrexone on craving level after rapid opioid detoxification induced by naltrexone. A naturalistic study was carried out in which patients were followed during 10 months after rapid detoxification. Data about abstinence, relapse, and naltrexone use were collected by means of urine specimens. Craving was measured by the visual analogue scale craving, the Obsessive Compulsive Drug Use Scale, and the Desires for Drug Questionnaire. Results showed that patients who relapsed in opioid use experienced obviously more craving than abstinent people. Patients who took naltrexone did not experience significant less craving than those who did not. These results suggest that the use of opioids is associated with increased craving and that abstinence for opioids is associated with less craving, independent of the use of naltrexone. This is in contrast to the general opinion. Because of the naturalistic design of the study, no firm conclusions can be drawn, but the results grounded the needs of an experimental study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17508990     DOI: 10.1111/j.1369-1600.2007.00067.x

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  8 in total

Review 1.  Pharmacological strategies for detoxification.

Authors:  Alison M Diaper; Fergus D Law; Jan K Melichar
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 2.  Maintenance medication for opiate addiction: the foundation of recovery.

Authors:  Gavin Bart
Journal:  J Addict Dis       Date:  2012

3.  Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans.

Authors:  Alex F Manini; Georgia Yiannoulos; Mateus M Bergamaschi; Stephanie Hernandez; Ruben Olmedo; Allan J Barnes; Gary Winkel; Rajita Sinha; Didier Jutras-Aswad; Marilyn A Huestis; Yasmin L Hurd
Journal:  J Addict Med       Date:  2015 May-Jun       Impact factor: 3.702

4.  Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

Authors:  Kenneth Blum; Edward J Modestino; Rajendra D Badgaiyan; David Baron; Panayotis K Thanos; Igor Elman; David Siwicki; Marcelo Febo; Mark S Gold
Journal:  EC Psychol Psychiatr       Date:  2018-07-30

Review 5.  Potential uses of naltrexone in emergency department patients with opioid use disorder.

Authors:  Evan Stuart Bradley; David Liss; Stephanie Pepper Carreiro; David Eric Brush; Kavita Babu
Journal:  Clin Toxicol (Phila)       Date:  2019-03-04       Impact factor: 4.467

Review 6.  Medications for Treatment of Opioid Use Disorder among Persons Living with HIV.

Authors:  Laura Fanucchi; Sandra A Springer; P Todd Korthuis
Journal:  Curr HIV/AIDS Rep       Date:  2019-02       Impact factor: 5.071

7.  Pharmacological enhancement of naltrexone treatment for opioid dependence: a review.

Authors:  Paolo Mannelli; Kathleen S Peindl; Li-Tzy Wu
Journal:  Subst Abuse Rehabil       Date:  2011-06

8.  Impact of Impulsivity, Hyperactivity, and Inattention on Discontinuation Rate among Opioid-Dependent Patients Treated with Extended-Release Naltrexone.

Authors:  Ann Tarja Karlsson; John-Kåre Vederhus; Thomas Clausen; Bente Weimand; Kristin Klemmetsby Solli; Lars Tanum
Journal:  Int J Environ Res Public Health       Date:  2022-09-11       Impact factor: 4.614

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.